cytokinetics - Search News

Stifel, Cytokinetics

Stifel Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 85.04% Upside As of December 23, 2024, the average one-year price target for Cytokinetics is $84.

Business Insider · 20h

Cytokinetics initiated with a Buy at Stifel

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the

Investing.com on MSN · 19h

Stifel starts Cytokinetics stock with Buy, $80 target

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of $80.00. The new coverage comes after a period of instability for the company,

Hosted on MSN · 2h

Cytokinetics started at buy by Stifel, aficamten highlighted

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty Pharma (RPRX) and no M&A,

19h

Cytokinetics Starts Trial For CK-586 In HFpEF

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...

STAT8d

Cytokinetics is not looking to be acquired, CEO says

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

news.stocktradersdaily18h

(CYTK) Technical Pivots with Risk Controls

Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...

Yahoo Finance5d

Cytokinetics, Incorporated (CYTK)

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...

The Business Journals29d

Cytokinetics' potential blockbuster heart drug flips to new partner in China

Cytokinetics could make more geography-centric deals as regulators in the United States, Europe and China review the company's potential blockbuster drug for approval. Cytokinetics Inc. has a new ...

pharmaphorum8d

Look out BMS, Cytokinetics has its eye on mavacamten's turf

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ...

15d

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.

10d

Cytokinetics’ (CYTK) Buy Rating Reiterated at HC Wainwright

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on ...

Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Stifel, Cytokinetics

Related topics